Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer

•Patients with stage IB-IIA non-small cell lung cancer is a group with heterogeneity•Patients with at least 2 risk factors have a higher risk of recurrence•Adjuvant chemotherapy can improve prognosis especially for patients with high risk•Patients with wild-type EGFR were benefited from adjuvant chemotherapy•Patients with non-squamous cell cancer were benefited from pemetrexed plus platinum.